Stockreport

Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma

JUNO THERAPEUTICS  (JUNO) 
Last juno therapeutics earnings: 11/1 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.junotherapeutics.com/investor-relations
PDF – First multicenter CAR T trial to treat a wide range of patients with aggressive relapsed or refractory NHL excluded from other trials – 66% (21 [Read more]